Health Condition 1: L639- Alopecia areata, unspecified
Conditions
Interventions
Intervention1: Oral Apremilast: Oral Apremilast 30 mg twice daily per oral route for 12 weeks in alopecia areata patients,
Under the dermatologist consultants discretion.
Intervention2: Systemic thera
Sponsors
Dr Vaishnavi Puri
Eligibility
Inclusion criteria
Inclusion criteria: Patients willing to give consent. Patients of alopecia areata with more than equal to 3 patches or scalp area involving more than 10% .
Exclusion criteria
Exclusion criteria: 1)Patients who have received topical and systemic medications for alopecia areata upto 1 month before. 2) Pregnant and lactating women. 3) Patients with history of active TB or incompletely treated TB. 4) Patients with psychiatric illness. 5) Patients with HIV, Hepatitis B and Malignancy. 6) History of serious side effects to phosphodiesterase type 4 inhibitors – Apremilast. 7) Patients with severe renal impairment, hepatic impairment cardiac diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| This study will measure hair regrowth in patients of alopecia areata after treatment with Oral apremilast and oral minipulse Betamethasone and signs noted on trichoscopy and improvement in SALT Score after completing 12 weeks of treatmentTimepoint: 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Check for any adverse effectsTimepoint: 4weeks ,8weeks & 12 weeks | — |
Countries
India
Contacts
Public ContactDr Kashinath Nayak
Kasturba Medical College ,Mangalore
Outcome results
None listed